Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

As Bayer preps for its slim-down, a restructuring looms–but jobs are safe, CEO says

Carly Helfand As Bayer moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's ...

Takeda preps for ‘stringent’ R&D as a new boss takes the reins

Damian Garde Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...

Elan spurns buyout offer, preps for deal spree

John Carroll Elan's ($ ELN) board of directors has rejected an $ 11.25-per-share bid by Royalty Pharma, sending a message along that it views the offer as far short of what the ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS